Experienced in Hepatic Ischemia

Mario R. Silva-Da

2400 Ramiro Barcelos Street, 
Porto Alegre, RS, BR 
Experienced in Hepatic Ischemia
2400 Ramiro Barcelos Street, 
Porto Alegre, RS, BR 
OverviewLocationsClinical Research

Overview

Mario Silva-Da practices in Porto Alegre, Brazil. Mr. Silva-Da is rated as an Experienced expert by MediFind in the treatment of Hepatic Ischemia. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Spontaneous Bacterial Peritonitis, Cirrhosis, Liver Transplant, and Liver Embolization.

His clinical research consists of co-authoring 145 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hepatic Ischemia.

Gender
Male

Locations

2400 Ramiro Barcelos Street, Porto Alegre, RS, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
Enrollment Status: Terminated
Publish Date: September 06, 2022
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 4
View 1 Less Clinical Trial

145 Total Publications

Oral apigenin prevents obesity-related muscular atrophy, but not obesity itself, in middle-aged rats fed a high-calorie diet.
Oral apigenin prevents obesity-related muscular atrophy, but not obesity itself, in middle-aged rats fed a high-calorie diet.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Silva-Da's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile